临床表现 临床表现
Marina Scop Madeiros1, Pamela C L Ferreira1, Bruna Bellaver1
1University of Pittsburgh, Pittsburgh, PA, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
概括
这项研究比较了阿尔茨海默氏症的两种TAU PET标记剂.
科学领域:
- 神经学 神经学
- 核医学就是核医学.
- 生物标志物 生物标志物
背景情况:
- 根据阿尔茨海默病协会 (AA-2024) 的标准,基于PET成像,提出了阿尔茨海默病 (AD) 的四个生物阶段.
- 型PET标记物的变化可以影响这些生物阶段的应用.
- 了解特定于追踪器的性能对于准确的AD分期至关重要.
研究的目的:
- 为了比较阿尔茨海默病的生物分期的诊断性能,使用两个不同的tau PET标记剂:MK-6240和Flortaucipir (FTP).
- 以AA-2024标准定义的AD临床和生物阶段之间的一致性进行评估.
- 评估不同TAU PET标记物对AD阶段分类的影响.
主要方法:
- 对446个人的分析,包括来自HEAD研究的167名Aβ阳性参与者,他们接受了MK-6240和Flortaucipir (FTP) PET扫描.
- 临床分期 (正常,过渡期,MCI,痴呆症) 基于AA-2024标准,特别关注第二阶段子组 (SCD,SOCD,MBI).
- 生物分期使用特定标记物值为两个区域的兴趣方案 (AA-2024和Braak阶段) 的区域SUVR;使用科恩的卡帕和计算的正预测值 (PPV) 评估协议.
主要成果:
- 这两种标志物都显示了粉样β (Aβ) 阳性和tau PET病理在临床阶段逐渐增加,从认知正常到痴呆.
- 主观认知衰退 (SCD) 和轻度行为障碍 (MBI) 亚组与认知正常个体相比没有增加病理.
- 微妙的客观认知衰退 (SOCD) 被确定为一个相关的过渡阶段 (阶段2),具有更高的病理负担;在临床和生物阶段之间观察到适度的一致性 (0.34-0.59),MK-6240在早期阶段显示较低的PPV比FTP.
结论:
- 当使用Flortaucipir或MK-6240PET标记剂时,AA-2024的生物和临床阶段显示出类似的一致性.
- 与SCD和MBI子组不同的是,SOCD过渡阶段与第一阶段相比,具有更高的病理负担.
- 研究结果支持这两种标志物对于AD分期的实用性,同时突出了依赖于方法的性能变化.
相关概念视频
Chronic Kidney Disease II: Clinical Manifestations
520
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
520
Coronary Artery Disease III: Clinical Manifestations
299
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
299
Endocarditis II: Clinical Features of Infective Endocarditis
364
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
364
Heart Failure III: Clinical Manifestations
436
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
436
Gastroesophageal Reflux Disease II: Clinical Features and Management
652
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
652
Hypertension III: Clinical Manifestations and Diagnostic Studies
437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437


